Modern approaches to drug treatment for vestibular vertigo
Abstract
In recent years, some progress has been achieved in elaborating the algorithms and standards for the treatment of many conditions accompanied by vertigo. The current possibilities of treating vestibular vertigo consist of a gradually expanding arsenal of symptomatic and pathogenetic drugs. Among the drugs used for the symptomatic treatment of vestibular vertigo, there are vestibular suppressants (antihistamines, benzodiazepines, and calcium antagonists) and antiemetics (dopamine antagonists and serotonin 5-HT3 receptor antagonists). The paper discusses the possibilities of using betahistine and vitamin D as pathogenetic agents for recurrent benign paroxysmal positional vertigo; diuretics, betahistine (including the new prolonged release formulation Betaserc® Long), glucocorticoids, and gentamicin for Meniere's disease; triptans, beta-blockers, tricyclic antidepressants, and anticonvulsants for vestibular migraine; glucocorticoids, antiviral agents, and drugs that accelerate vestibular compensation for acute unilateral peripheral vestibulopathy (vestibular neuritis and Ramsey Hunt syndrome).
The emergence of new drugs, as well as the design of new dosage forms that enhance patient adherence to the prescribed treatment, can improve quality of life in patients suffering from diseases that have recently led to long-term disability or even incapacitation.
About the Authors
M. V. Zamergrad
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Maksim Valeryevich Zamergrad
Department of Neurology with Course of Reflexology and Manual Therapy; Russian Gerontology Research and Clinical Center
2/1, Barrikadnaya St., Build. 1, Moscow 125993
1, Ostrovityanov St., Moscow 117997
S. V. Morozova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
8, Trubetskaya St., Build 2, Moscow 119991
Russian Federation
8, Trubetskaya St., Build 2, Moscow 119991
References
1. Parfenov VA, Zamergrad MV, Melnikov OA. Golovokruzheniye: diagnostika i lecheniye, rasprostranennyye diagnosticheskiye oshibki [Dizziness: diagnosis and management, common pitfalls]. 3 rd ed. Moscow: MIA; 2019. 208 p. (In Russ.).
2. Strupp M, Mandala M, Lopez-Escаmez JA. Peripheral vestibular disorders: an update. Curr Opin Neurol. 2019 Feb;32(1):165-73. doi: 10.1097/WCO.0000000000000649
3. Muncie HL, Sirmans SM, Dizziness JE. Approach to Evaluation and Management. Am Fam Physician. 2017;95(3):154-62.
4. Hain TC, Uddin M. Pharmacological treatment of vertigo. CNS Drugs. 2003;17(2):85-100. doi: 10.2165/00023210-200317020-00002
5. Scholtz AW, Ilgner J, Loader B, et al. Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice. Wien Klin Wochenschr. 2016 May;128(9-10):341-7. doi: 10.1007/s00508-015-0905-5. Epub 2015 Dec 11.
6. Amini A, Heidari K, Asadollahi S, et al. Intravenous promethazine versus lorazepam for the treatment of peripheral vertigo in the emergency department: A double blind, randomized clinical trial of efficacy and safety. J Vestib Res. 2014;24(1):39-47. doi: 10.3233/VES-130506
7. Taghdiri F, Togha M, Razeghi Jahromi S, Refaeian F. Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study. Springerplus. 2014 May 7;3:231. doi: 10.1186/2193-1801-3-231
8. Cesarani A, Alpini D, Monti B, Raponi G; ENT Department, University of Milan, Milan, Italy. The treatment of acute vertigo. Neurol Sci. 2004 Mar;25 Suppl 1:S26-30. doi: 10.1007/s10072-004-0213-8
9. Lacour M, Helmchen C, Vidal PP. Vestibular compensation: the neuro-otologist's best friend. J Neurol. 2016 Apr;263 Suppl 1:S54-64. doi: 10.1007/s00415-015-7903-4. Epub 2016 Apr 15.
10. Venail F, Biboulet R, Mondain M, Uziel A. A protective effect of 5-HT3 antagonist against vestibular deficit? Metoclopramide versus ondansetron at the early stage of vestibular neuritis: a pilot study. Eur Ann Otorhinolaryngol Head Neck Dis. 2012 Apr;129(2):65-8. doi: 10.1016/j.anorl.2011.10.006
11. Dyhrfjeld-Johnsen J, Gaboyard-Niay S, Broussy A, et al. Ondansetron reduces lasting vestibular deficits in a model of severe peripheral excitotoxic injury. J Vestib Res. 2013;23(3):177-86. doi: 10.3233/VES-130483
12. Guneri EA, Kustutan O. The effects of betahistine in addition to epley maneuver in posterior canal benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. 2012 Jan;146(1):104-8. doi: 10.1177/0194599811419093. Epub 2011 Aug 18.
13. Jalali MM, Gerami H, Saberi A, Razaghi S. The Impact of Betahistine versus Dimenhydrinate in the Resolution of Residual Dizziness in Patients with Benign Paroxysmal Positional Vertigo: A Randomized Clinical Trial. Ann Otol Rhinol Laryngol. 2020 May;129(5):434-40. doi: 10.1177/0003489419892285. Epub 2019 Dec 6.
14. AlGarni MA, Mirza AA, Althobaiti AA, et al. Association of benign paroxysmal positional vertigo with vitamin D deficiency: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2018 Nov;275(11):2705-11. doi: 10.1007/s00405-018-5146-6. Epub 2018 Oct 9.
15. Talaat HS, Kabel AM, Khaliel LH, et al. Reduction of recurrence rate of benign paroxysmal positional vertigo by treatment of severe vitamin D deficiency. Auris Nasus Larynx. 2016 Jun;43(3):237-41. doi: 10.1016/j.anl.2015.08.009. Epub 2015 Sep 16.
16. Jeong SH, Kim JS, Kim HJ, et al. Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: A randomized trial. Neurology. 2020 Sep 1;95(9):e1117-e1125. doi: 10.1212/WNL.0000000000010343. Epub 2020 Aug 5.
17. Sepahdari AR, Vorasubin N, Ishiyama G, Ishiyama A. Endolymphatic Hydrops Reversal following Acetazolamide Therapy: Demonstration with Delayed Intravenous Contrast-Enhanced 3D-FLAIR MRI. AJNR Am J Neuroradiol. 2016 Jan;37(1):151-4. doi: 10.3174/ajnr.A4462
18. Thirlwall AS, Kundu S. Diuretics for Meniere's disease or syndrome. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003599. doi: 10.1002/14651858.CD003599.pub2
19. Crowson MG, Patki A, Tucci DL. A Systematic Review of Diuretics in the Medical Management of Meniere's Disease. Otolaryngol Head Neck Surg. 2016 May;154(5):824-34. doi: 10.1177/0194599816630733. Epub 2016 Mar 1.
20. Nauta JJ. Meta-analysis of clinical studies with betahistine in Meniere's disease and vestibular vertigo. Eur Arch Otorhinolaryngol. 2014 May;271(5):887-97. doi: 10.1007/s00405013-2596-8. Epub 2013 Jun 19.
21. Strupp M, Hupert D, Frenzel C, et al. Long-term prophylactic treatment of attacks of vertigo in Meniere's disease – comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol. 2008 May;128(5):520-4. doi: 10.1080/00016480701724912
22. Mira E, Guidetti G, Ghilardi L, et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol. 2003 Feb;260(2):73-7. doi: 10.1007/s00405-002-0524-4. Epub 2002 Sep 11.
23. Parfenov VA, Golyk VA, Matsnev EI, et al. Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study. PLoS One. 2017 Mar 30;12(3):e0174114. doi: 10.1371/journal.pone.0174114. eCollection 2017.
24. Magnan J, Еzgirgin ON, Trabalzini F, et al. European Position Statement on Diagnosis, and Treatment of Meniere's Disease. J Int Adv Otol. 2018 Aug;14(2):317-21. doi: 10.5152/iao.2018.140818
25. Basura GJ, Adams ME, Monfared A, et al. Clinical Practice Guideline: Mеniеre's Disease Executive Summary. Otolaryngol Head Neck Surg. 2020 Apr;162(4):415-34. doi: 10.1177/0194599820909439
26. Parfenov VA, Zamergrad MV, Kazey DV, Nauta Y. Study of the efficacy and safety of a new form of betahistine with modified release in the treatment of vestibular vertigo and Meniere's disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(12):42-8. doi: 10.17116/jnevro202012012142 (In Russ.).
27. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Betaserk ® Long. tabletki s modifitsirovannym vysvobozhdeniyem. pokrytyye plenochnoy obolochkoy. 48 mg (Ebbott Prodakts Opereyshnz EyDzhi. Shveytsariya). Registratsionnyy nomer: LP-006452. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e9a13fa6-0d53-4aa5-930329a46779a51c&t= (In Russ.)
28. Kaya I, Eraslan S, Tarhan C, et al. Can verapamil be effective in controlling vertigo and headache attacks in vestibular migraine accompanied with Meniere's disease? A preliminary study. J Neurol. 2019 Sep;266(Suppl 1):62-4. doi: 10.1007/s00415-019-09309-w. Epub 2019 Apr 15.
29. Rask-Andersen H, Friberg U, Johansson M, Stjernschantz J. Effects of intratympanic injection of latanoprost in Meniere's disease: a randomized, placebo-controlled, double-blind, pilot study. Otolaryngol Head Neck Surg. 2005 Sep;133(3):441-3. doi: 10.1016/j.otohns.2005.05.043
30. Lempert T, Olesen J, Furman J, et al. Vestibular migraine: diagnostic criteria. J Vestib Res. 2012;22(4):167-72. doi: 10.3233/VES2012-0453
31. Maldonado Fernandez M, Birdi JS, Irving GJ, et al. Pharmacological agents for the prevention of vestibular migraine. Cochrane Database Syst Rev. 2015 Jun 21;2015(6):CD010600. doi: 10.1002/14651858.CD010600.pub2
32. Furman JM, Marcus DA, Balaban CD. Rizatriptan reduces vestibular-induced motion sickness in migraineurs. J Headache Pain. 2011 Feb;12(1):81-8. doi: 10.1007/s10194-010-0250z. Epub 2010 Sep 23.
33. Lauritsen CG, Marmura MJ. Current Treatment Options: Vestibular Migraine. Curr Treat Options Neurol. 2017 Sep 30;19(11):38. doi: 10.1007/s11940-017-0476-z
34. Lapira A. Vestibular migraine treatment and prevention. HNO. 2019 Jun;67(6):425-8. doi: 10.1007/s00106-019-0661-3
35. Balaban CD, Black RD, Silberstein SD. Vestibular Neuroscience for the Headache Specialist. Headache. 2019 Jul;59(7):1109-27. doi: 10.1111/head.13550. Epub 2019 May 11.
36. Lempert T, von Brevern M. Vestibular Migraine. Neurol Clin. 2019 Nov;37(4):695-706. doi: 10.1016/j.ncl.2019.06.003. Epub 2019 Aug 20.
37. Le TN, Westerberg BD, Lea J. Vestibular Neuritis: Recent Advances in Etiology, Diagnostic Evaluation, and Treatment. Adv Otorhinolaryngol. 2019;82:87-92. doi: 10.1159/000490275. Epub 2019 Jan 15.
38. Sjögren J, Magnusson M, Tjernström F, Karlberg M. Steroids for Acute Vestibular Neuronitis-the Earlier the Treatment, the Better the Outcome? Otol Neurotol. 2019 Mar;40(3):372-4. doi: 10.1097/MAO.0000000000002106
39. Strupp M, Zingler VC, Arbusow V, et al. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med. 2004 Jul 22;351(4):354-61. doi: 10.1056/NEJMoa033280
40. Guseva AL, Zamergrad MV, Levin OS. Ramsay Hunt syndrome. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(9):151-7. doi: 10.17116/jnevro2020120091151 (In Russ.).
41. Zainine R, Sellami M, Charfeddine A, et al. Ramsay Hunt syndrome. Eur Ann Otorhinolaryngol Head Neck Dis. 2012 Feb;129(1):22-5. doi: 10.1016/j.anorl.2011.08.003. Epub 2012 Feb 24.
42. Redon C, Lopez C, Bernard-Demanze L. Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. J Clin Pharmacol. 2011 Apr;51(4):538-48. doi: 10.1177/0091270010369241. Epub 2010 Oct 12.
43. Hamann KF. Special ginkgo extract in cases of vertigo: a systematic review of randomised, double-blind, placebo controlled clinical examinations. HNO. 2007;55(4):258-63. doi: 10.1007/s00106-006-1440-5
Review
Supporting agencies: This article has been supported by Abbott. The sponsor has participated in the development of the investigation project and supported the investigation program, as well as in the decision to submit the article for publication.
For citations:
Zamergrad M.V., Morozova S.V. Modern approaches to drug treatment for vestibular vertigo. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):101-106. (In Russ.) https://doi.org/10.14412/2074-2711-2021-1-101-106
Views: 989
Email this article 